CEL-SCI Corp - Asset Resilience Ratio
CEL-SCI Corp (CVM) has an Asset Resilience Ratio of 27.45% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how CEL-SCI Corp's Asset Resilience Ratio has changed over time. Check CEL-SCI Corp PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down CEL-SCI Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CVM market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $6.28 Million | 27.42% |
| Short-term Investments | $7.09K | 0.03% |
| Total Liquid Assets | $6.28 Million | 27.45% |
Asset Resilience Insights
- Very High Liquidity: CEL-SCI Corp maintains exceptional liquid asset reserves at 27.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
CEL-SCI Corp Industry Peers by Asset Resilience Ratio
Compare CEL-SCI Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 5.66% |
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.34% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 43.36% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
REMEGEN CO. LTD YC 1
F:REG |
Biotechnology | 16.77% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for CEL-SCI Corp (1999–2025)
The table below shows the annual Asset Resilience Ratio data for CEL-SCI Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-09-30 | 38.93% | $10.96 Million | $28.16 Million | +21.36pp |
| 2024-09-30 | 17.57% | $4.74 Million | $26.99 Million | +3.99pp |
| 2023-09-30 | 13.58% | $4.15 Million | $30.53 Million | -31.29pp |
| 2022-09-30 | 44.87% | $22.67 Million | $50.52 Million | -10.76pp |
| 2021-09-30 | 55.64% | $42.21 Million | $75.87 Million | +17.38pp |
| 2020-09-30 | 38.26% | $15.51 Million | $40.54 Million | +7.69pp |
| 2019-09-30 | 30.57% | $8.44 Million | $27.62 Million | -4.28pp |
| 2018-09-30 | 34.85% | $10.31 Million | $29.59 Million | +24.51pp |
| 2017-09-30 | 10.34% | $2.37 Million | $22.92 Million | -16.16pp |
| 2016-09-30 | 26.50% | $3.07 Million | $11.60 Million | -- |
| 2015-09-30 | 0.00% | $0.00 | $15.45 Million | -- |
| 2014-09-30 | 0.00% | $0.00 | $19.23 Million | -- |
| 2013-09-30 | 0.00% | $0.00 | $10.84 Million | -- |
| 2012-09-30 | 0.00% | $0.00 | $16.07 Million | -- |
| 2011-09-30 | 0.00% | $0.00 | $18.63 Million | -- |
| 2009-09-30 | 3.44% | $1.59 Million | $46.03 Million | +2.08pp |
| 2008-09-30 | 1.36% | $200.00K | $14.68 Million | -11.80pp |
| 2001-09-30 | 13.16% | $593.38K | $4.51 Million | -14.08pp |
| 2000-09-30 | 27.24% | $3.76 Million | $13.81 Million | -14.87pp |
| 1999-09-30 | 42.11% | $3.20 Million | $7.60 Million | -- |
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more